The FDA has granted fast track designation to EO2463, an off-the-shelf OncoMimics™ active immunotherapy vaccine, for patients with follicular lymphoma in the low tumor burden “watch-and-wait” setting, according to a press release from the developer, Enterome.1 EO2463 combines 4 synthetic peptides that correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with CD20, CD22, CD37, and CD268, the B lymphocyte-specific lineage markers; it also utilizes the CD4+ epitope helper peptide...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Forat
Contact Forat, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack